Advertiser Disclosure: We may earn commissions from partner links at no cost to you. This never affects our editorial content or recommendations.

Healthcare AI NYSE: NVO

Novo Nordisk A/S (NVO)

The original GLP-1 innovator navigating competition from Lilly while building next-generation obesity drugs.

✓ Reviewed by AI Decoded Editorial Team Updated March 2026
← All Healthcare AI Stocks

The AI Angle

Novo Nordisk invented the GLP-1 drug category and built two blockbuster franchises: Ozempic (semaglutide, diabetes) and Wegovy (semaglutide, obesity). Combined, these drugs generated approximately $33 billion in annualized revenue as of mid-2025. However, 2025 was a year of recalibration: Novo lowered its full-year guidance four times as US market growth slowed, Lilly's tirzepatide gained share, and compounded semaglutide from telehealth players ate into branded prescriptions. Full-year 2025 sales reached approximately $46.8 billion, up ~11% year-over-year.

The forward battleground is next-generation obesity treatments. Novo's CagriSema (cagrilintide + semaglutide combination) is in late-stage trials targeting 25%+ weight loss — competitive with Lilly's retatrutide. Novo is also investing in AI for drug discovery through its Oxford-based research collaborations and has announced plans to slash US GLP-1 list prices by up to 70% to compete with compounders and expand market access. The obesity drug market is projected to reach $130+ billion by 2030, and Novo remains one of two companies at the frontier.

Key Numbers

~$46.8B
2025 Full Year Revenue
+11% YoY in USD (MacroTrends)
+10%
2025 Sales Growth at CER
Constant exchange rate; in-line with lowered guidance
~$14.8B combined
Ozempic + Wegovy H1 2025
Ozempic ~$9.4B, Wegovy ~$5.4B (Drug Discovery Trends)

Sources: CNBC (Feb 3, 2026), Novo Nordisk Annual Report 2025, MacroTrends, Drug Discovery Trends (Nov 2025)

Upcoming Catalysts

  • CagriSema Phase 3 data — 25%+ weight loss potential, superior to current semaglutide
  • US GLP-1 price cuts (up to 70%) to regain volume from compounders
  • Oral semaglutide (Rybelsus) ramp and next-gen oral formulations
  • International Wegovy launch expanding into Europe, Canada, and Asia

Key Risks

  • Lilly's tirzepatide gaining share — superior efficacy narrative pressuring Wegovy
  • Slowing US demand growth: telehealth compounders providing cheaper alternatives
  • FDA scrutiny of compounded semaglutide may not materially benefit branded drugs
  • Patent expiry: Ozempic and Wegovy face generics by early 2030s

⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.